FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the
"Company"), today announced the appointment of James A. Datin and
Robert J. Ciaruffoli, CPA to the Company’s Board of Directors.

“It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD
Pharma Board of Directors,” said Dr.
Raza Bokhari, Executive Co-Chairman and CEO. “The experience and
expertise they both bring as c-level entrepreneurial executives,
leaders and board members of impressive organizations will add
tremendous value to FSD. Both gentlemen have been instrumental in
achieving outstanding growth for their respective companies, in raising
capital to fuel growth opportunities and in driving sustainable
shareholder value.”

“I’m pleased to be joining the FSD Pharma Board of Directors,” said
Mr. Datin. “The opportunity to contribute at this stage in FSD’s growth
is exciting. As a biotech life sciences
executive with extensive experience as a member of more than 30 Board of
Directors of PE backed and public companies, I am looking forward to
helping the leadership and Biosciences Division in realizing FSD’s
vision to meaningfully advance into the biopharmaceutical industry.”

“I am very happy to join the board of Directors. The cannabinoid
ecosystem is evolving at a very rapid pace and FSD’s leadership focus to
incorporate good governance and independence at FSD Board level is very
impressive; my lifetime experience as an auditor and accountant I
believe is a timely addition” added Mr. Ciaruffoli.

Over the course of his 30+ year career, James A. Datin has been a
successful CEO, raised capital for entrepreneurs
to grow companies, and has managed companies throughout the
United States, Europe and Asia. He has also completed more than 50
transactions including venture investments, buyouts, acquisitions,
mergers, IPOs, licensing and partnership agreements.

Mr. Datin is the current President & Chief Executive Officer
of BioAgilytix, a leading global bioanalytical contract research
organization (CRO) that supports the development of novel therapeutic
biologics. Since he became CEO, BioAgilytix has grown its customer base
and significantly increased its facility footprint and capacity,
including expansion to Europe with the acquisition of Hamburg-based
laboratory IPM Biotech. With his leadership, the company has been named
to the Inc. 5000 list of Fastest Growing Private Companies in America six
times, was named CRO of the Year in North Carolina, and has achieved
industry-leading customer satisfaction as measured by an independent
marketing firm. BioAgilytix was recently acquired by Cobepa, a PE fund.

Mr. Datin was previously EVP and Managing Director at Safeguard
Scientifics, Inc., where he led the Deal/investment team. He was also
CEO of Touchpoint Solutions and is a former board member of Intralinks,
where he chaired the audit committee. The company was acquired by TA &
Associates. Jim was also Chairman of the Board for five years at
Clarient, a cancer diagnostics company, when it was acquired by GE
Healthcare in December 2010. In addition, Jim was Chairman of the Board
of Laureate Pharma.

Mr. Datin holds an Advanced Management Degree from the Wharton School at
The University of Pennsylvania, a Master of Business Administration
Degree from the University of New Haven and a Bachelor of Business
Administration Degree from Marshall University.

Robert J. Ciaruffoli is a co-founder and vice-chairman of Broad Street
Angels, a 100 member Philadelphia based angel investor network which
invests in start-up entrepreneurial businesses with high growth
potential. Broad Street Angels is the largest angel investor network in
the Philadelphia region.

Mr. Ciaruffoli is a CPA and served as the chairman and CEO of the
Parente Beard/Baker Tilly accounting and advisory firm.
During his tenure as chairman and CEO, he and his team transitioned the
firm from a Pennsylvania practice to a multi-state super-regional firm.
In 2014, he orchestrated a merger of the Parente Beard and Baker Tilly
Virchow Krause firms to create the 12th largest US accounting and
advisory firm.

Mr. Ciaruffoli also served on the board of directors and executive
committee of Baker Tilly International, the eighth largest global
accounting network. During his tenure on the board and the executive
committee, Baker Tilly International grew from an unranked network to
the eighth largest global accounting network.

Throughout his career, Mr. Ciaruffoli has served on numerous for-profit
and not-for-profit boards. Presently, he is the President of the board
of directors of The Pennsylvania Society, a board member of Ben Franklin
Technology Partners, a board member of eureQa - a SaaS cloud based
automated platform for testing digital applications, and a member of the
finance committee of the Archdiocese of Philadelphia. He was also the
past chairman of the Pennsylvania State Board of Accountancy.

Mr. Ciaruffoli holds a Bachelor of Science in Accounting from Kings
College, Wilkes-Barre, Pennsylvania and has proudly served in the United
States Marine Corps (1970 – 1972).

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet that is licensed at its
Ontario facility and expansion is currently underway.

FSD facilities sit on 70 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet
by 2025.

FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017 and its Sale for Medical Purposes license on
April 18, 2019. FV Pharma's vision is to transform its current
headquarters in a Kraft plant in Cobourg, Ontario into the largest
hydroponic indoor grow facility in the world. FV Pharma intends to cover
all aspects of this exciting new industry, including cultivation, legal,
processing, manufacturing, extracts and research and development. For
additional information on the company, please visit our website at www.fsdpharma.com.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation services
provider accept responsibility for the adequacy or accuracy of this
release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005278/en/